A Phase II, Multi-Center, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Hemoglobin-Based Oxygen Carrier-201 (HBOC-201, hemoglobin-glutamer-250 (bovine)]) on Wound Healing in Patients with Peripheral Vascular Disease and Who are Undergoing a Lower Limb Amputation due to Critical Lower Limb Ischemia (Phase II - Safety and Feasibility)
Latest Information Update: 29 Jul 2020
At a glance
- Drugs Hemoglobin glutamer (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral vascular disorders
- Focus Adverse reactions
- Sponsors Biopure Corporation
- 29 Jul 2020 New trial record